WHAT THE HUMAN DATA SAY
Evidence before enthusiasm.
There is no established evidence that young plasma or routine plasma exchange makes healthy people younger or live longer. Biomarker shifts are not proof of durable clinical benefit.
This grade reflects clinically meaningful human evidence for the use described here. It is not a score for popularity, mechanism, animal lifespan results or the number of products already being sold.
HOW IT FITS
A practical role—without pretending it is universal.
Only consider within an appropriate medical indication or registered, ethically reviewed research study.
TRACK WHAT MATTERS
Know whether it is creating value.
Trial design and control group
Clinical outcomes beyond biomarkers
Adverse events and durability
SAFETY & BOUNDARIES
What should make you pause.
- Risks include bleeding, infection, allergic reactions, low blood pressure, electrolyte problems and line complications.
- FDA has warned against unproven young-plasma infusions.
BOOK CONNECTIONS
Where this idea enters the longevity conversation.
Book inclusion explains why the idea is culturally important; the evidence grade above determines how strongly The Modern Bio treats the claim.